Soft threshold partial least squares predicts the survival fraction of malignant glioma cells against different concentrations of methotrexate’s derivatives
Chemotherapy appeared to be a significant advancement in cancer research, with fewer side effects. Methotrexate (MTX) is a widely used anticancer drug with strong activity but serious side effects. Several MTX derivatives have been reported, with modifications at various sites to reduce side effects...
Saved in:
| Published in: | Scientific reports Vol. 11; no. 1; p. 18741 |
|---|---|
| Main Authors: | , |
| Format: | Journal Article |
| Language: | English |
| Published: |
London
Nature Publishing Group UK
21-09-2021
Nature Publishing Group Nature Portfolio |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Chemotherapy appeared to be a significant advancement in cancer research, with fewer side effects. Methotrexate (MTX) is a widely used anticancer drug with strong activity but serious side effects. Several MTX derivatives have been reported, with modifications at various sites to reduce side effects and increase efficacy. The current study uses FTIR spectroscopy to predict the survival fraction of human malignant glioma U87 (MG-U87) cell lines against MTX derivatives. Together with Parent MTX several aldehydes viz. Benzaldehyde, Chlorobenzaldehyde, 2-Chlorobenzaldehyde, 3-Nitrobenzaldehyde, 5-Chloro-2-hydroxybenz-aldehyde, 2-Hydroxy-5-Nitrobenzaldehyde, 2-Thiocarboxyaldehyde, Trans-2-pentenal, and Glutaraldehyde are treated with MTX to obtain MTX derivatives. The prediction of survival fraction of malignant glioma cells is carried out by Lasso, Elastic net and Soft PLS at different concentration levels of synthesized derivatives, including 400 μM, 200 μM, 100 μM, 50 μM, 25 μM and 12.5 μM. The cross-validated prediction error is minimised to optimise spectral wavelength selection and model parameters. It appears that the RMSE computed from test data is significantly varying with the change of models (p = 0.012), with the change of concentrations levels (p
≤
0.001
) and with the change of combination of models and concentration level (p
≤
0.001
). StPLS outperforms in predicting survival fraction of glioma cells at the concentration level 50 μM, 100 μM and 400 μM respectively with relative RMSE = 0.1,0.14 and 0.55. Lasso outperforms at the concentration level 12.5 μM, and 200 μM respectively with relative RMSE = 0.4 and 0.14. Elastic net outperforms at the concentration level 25 μM with relative RMSE = 0.8. Consistently appeared influential wavelength identifies the influential functional compounds which best predicts the survival fraction. Hence FTIR appears potential candidate for estimating survival fraction of MTX derivatives. |
|---|---|
| AbstractList | Chemotherapy appeared to be a significant advancement in cancer research, with fewer side effects. Methotrexate (MTX) is a widely used anticancer drug with strong activity but serious side effects. Several MTX derivatives have been reported, with modifications at various sites to reduce side effects and increase efficacy. The current study uses FTIR spectroscopy to predict the survival fraction of human malignant glioma U87 (MG-U87) cell lines against MTX derivatives. Together with Parent MTX several aldehydes viz. Benzaldehyde, Chlorobenzaldehyde, 2-Chlorobenzaldehyde, 3-Nitrobenzaldehyde, 5-Chloro-2-hydroxybenz-aldehyde, 2-Hydroxy-5-Nitrobenzaldehyde, 2-Thiocarboxyaldehyde, Trans-2-pentenal, and Glutaraldehyde are treated with MTX to obtain MTX derivatives. The prediction of survival fraction of malignant glioma cells is carried out by Lasso, Elastic net and Soft PLS at different concentration levels of synthesized derivatives, including 400 μM, 200 μM, 100 μM, 50 μM, 25 μM and 12.5 μM. The cross-validated prediction error is minimised to optimise spectral wavelength selection and model parameters. It appears that the RMSE computed from test data is significantly varying with the change of models (p = 0.012), with the change of concentrations levels (p [Formula: see text]) and with the change of combination of models and concentration level (p [Formula: see text]). StPLS outperforms in predicting survival fraction of glioma cells at the concentration level 50 μM, 100 μM and 400 μM respectively with relative RMSE = 0.1,0.14 and 0.55. Lasso outperforms at the concentration level 12.5 μM, and 200 μM respectively with relative RMSE = 0.4 and 0.14. Elastic net outperforms at the concentration level 25 μM with relative RMSE = 0.8. Consistently appeared influential wavelength identifies the influential functional compounds which best predicts the survival fraction. Hence FTIR appears potential candidate for estimating survival fraction of MTX derivatives. Abstract Chemotherapy appeared to be a significant advancement in cancer research, with fewer side effects. Methotrexate (MTX) is a widely used anticancer drug with strong activity but serious side effects. Several MTX derivatives have been reported, with modifications at various sites to reduce side effects and increase efficacy. The current study uses FTIR spectroscopy to predict the survival fraction of human malignant glioma U87 (MG-U87) cell lines against MTX derivatives. Together with Parent MTX several aldehydes viz. Benzaldehyde, Chlorobenzaldehyde, 2-Chlorobenzaldehyde, 3-Nitrobenzaldehyde, 5-Chloro-2-hydroxybenz-aldehyde, 2-Hydroxy-5-Nitrobenzaldehyde, 2-Thiocarboxyaldehyde, Trans-2-pentenal, and Glutaraldehyde are treated with MTX to obtain MTX derivatives. The prediction of survival fraction of malignant glioma cells is carried out by Lasso, Elastic net and Soft PLS at different concentration levels of synthesized derivatives, including 400 μM, 200 μM, 100 μM, 50 μM, 25 μM and 12.5 μM. The cross-validated prediction error is minimised to optimise spectral wavelength selection and model parameters. It appears that the RMSE computed from test data is significantly varying with the change of models (p = 0.012), with the change of concentrations levels (p $$\le 0.001$$ ≤ 0.001 ) and with the change of combination of models and concentration level (p $$\le 0.001$$ ≤ 0.001 ). StPLS outperforms in predicting survival fraction of glioma cells at the concentration level 50 μM, 100 μM and 400 μM respectively with relative RMSE = 0.1,0.14 and 0.55. Lasso outperforms at the concentration level 12.5 μM, and 200 μM respectively with relative RMSE = 0.4 and 0.14. Elastic net outperforms at the concentration level 25 μM with relative RMSE = 0.8. Consistently appeared influential wavelength identifies the influential functional compounds which best predicts the survival fraction. Hence FTIR appears potential candidate for estimating survival fraction of MTX derivatives. Chemotherapy appeared to be a significant advancement in cancer research, with fewer side effects. Methotrexate (MTX) is a widely used anticancer drug with strong activity but serious side effects. Several MTX derivatives have been reported, with modifications at various sites to reduce side effects and increase efficacy. The current study uses FTIR spectroscopy to predict the survival fraction of human malignant glioma U87 (MG-U87) cell lines against MTX derivatives. Together with Parent MTX several aldehydes viz. Benzaldehyde, Chlorobenzaldehyde, 2-Chlorobenzaldehyde, 3-Nitrobenzaldehyde, 5-Chloro-2-hydroxybenz-aldehyde, 2-Hydroxy-5-Nitrobenzaldehyde, 2-Thiocarboxyaldehyde, Trans-2-pentenal, and Glutaraldehyde are treated with MTX to obtain MTX derivatives. The prediction of survival fraction of malignant glioma cells is carried out by Lasso, Elastic net and Soft PLS at different concentration levels of synthesized derivatives, including 400 μM, 200 μM, 100 μM, 50 μM, 25 μM and 12.5 μM. The cross-validated prediction error is minimised to optimise spectral wavelength selection and model parameters. It appears that the RMSE computed from test data is significantly varying with the change of models (p = 0.012), with the change of concentrations levels (p ≤0.001) and with the change of combination of models and concentration level (p ≤0.001). StPLS outperforms in predicting survival fraction of glioma cells at the concentration level 50 μM, 100 μM and 400 μM respectively with relative RMSE = 0.1,0.14 and 0.55. Lasso outperforms at the concentration level 12.5 μM, and 200 μM respectively with relative RMSE = 0.4 and 0.14. Elastic net outperforms at the concentration level 25 μM with relative RMSE = 0.8. Consistently appeared influential wavelength identifies the influential functional compounds which best predicts the survival fraction. Hence FTIR appears potential candidate for estimating survival fraction of MTX derivatives. Chemotherapy appeared to be a significant advancement in cancer research, with fewer side effects. Methotrexate (MTX) is a widely used anticancer drug with strong activity but serious side effects. Several MTX derivatives have been reported, with modifications at various sites to reduce side effects and increase efficacy. The current study uses FTIR spectroscopy to predict the survival fraction of human malignant glioma U87 (MG-U87) cell lines against MTX derivatives. Together with Parent MTX several aldehydes viz. Benzaldehyde, Chlorobenzaldehyde, 2-Chlorobenzaldehyde, 3-Nitrobenzaldehyde, 5-Chloro-2-hydroxybenz-aldehyde, 2-Hydroxy-5-Nitrobenzaldehyde, 2-Thiocarboxyaldehyde, Trans-2-pentenal, and Glutaraldehyde are treated with MTX to obtain MTX derivatives. The prediction of survival fraction of malignant glioma cells is carried out by Lasso, Elastic net and Soft PLS at different concentration levels of synthesized derivatives, including 400 μM, 200 μM, 100 μM, 50 μM, 25 μM and 12.5 μM. The cross-validated prediction error is minimised to optimise spectral wavelength selection and model parameters. It appears that the RMSE computed from test data is significantly varying with the change of models (p = 0.012), with the change of concentrations levels (p \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\le 0.001$$\end{document} ≤ 0.001 ) and with the change of combination of models and concentration level (p \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\le 0.001$$\end{document} ≤ 0.001 ). StPLS outperforms in predicting survival fraction of glioma cells at the concentration level 50 μM, 100 μM and 400 μM respectively with relative RMSE = 0.1,0.14 and 0.55. Lasso outperforms at the concentration level 12.5 μM, and 200 μM respectively with relative RMSE = 0.4 and 0.14. Elastic net outperforms at the concentration level 25 μM with relative RMSE = 0.8. Consistently appeared influential wavelength identifies the influential functional compounds which best predicts the survival fraction. Hence FTIR appears potential candidate for estimating survival fraction of MTX derivatives. Chemotherapy appeared to be a significant advancement in cancer research, with fewer side effects. Methotrexate (MTX) is a widely used anticancer drug with strong activity but serious side effects. Several MTX derivatives have been reported, with modifications at various sites to reduce side effects and increase efficacy. The current study uses FTIR spectroscopy to predict the survival fraction of human malignant glioma U87 (MG-U87) cell lines against MTX derivatives. Together with Parent MTX several aldehydes viz. Benzaldehyde, Chlorobenzaldehyde, 2-Chlorobenzaldehyde, 3-Nitrobenzaldehyde, 5-Chloro-2-hydroxybenz-aldehyde, 2-Hydroxy-5-Nitrobenzaldehyde, 2-Thiocarboxyaldehyde, Trans-2-pentenal, and Glutaraldehyde are treated with MTX to obtain MTX derivatives. The prediction of survival fraction of malignant glioma cells is carried out by Lasso, Elastic net and Soft PLS at different concentration levels of synthesized derivatives, including 400 μM, 200 μM, 100 μM, 50 μM, 25 μM and 12.5 μM. The cross-validated prediction error is minimised to optimise spectral wavelength selection and model parameters. It appears that the RMSE computed from test data is significantly varying with the change of models (p = 0.012), with the change of concentrations levels (p ≤ 0.001 ) and with the change of combination of models and concentration level (p ≤ 0.001 ). StPLS outperforms in predicting survival fraction of glioma cells at the concentration level 50 μM, 100 μM and 400 μM respectively with relative RMSE = 0.1,0.14 and 0.55. Lasso outperforms at the concentration level 12.5 μM, and 200 μM respectively with relative RMSE = 0.4 and 0.14. Elastic net outperforms at the concentration level 25 μM with relative RMSE = 0.8. Consistently appeared influential wavelength identifies the influential functional compounds which best predicts the survival fraction. Hence FTIR appears potential candidate for estimating survival fraction of MTX derivatives. Chemotherapy appeared to be a significant advancement in cancer research, with fewer side effects. Methotrexate (MTX) is a widely used anticancer drug with strong activity but serious side effects. Several MTX derivatives have been reported, with modifications at various sites to reduce side effects and increase efficacy. The current study uses FTIR spectroscopy to predict the survival fraction of human malignant glioma U87 (MG-U87) cell lines against MTX derivatives. Together with Parent MTX several aldehydes viz. Benzaldehyde, Chlorobenzaldehyde, 2-Chlorobenzaldehyde, 3-Nitrobenzaldehyde, 5-Chloro-2-hydroxybenz-aldehyde, 2-Hydroxy-5-Nitrobenzaldehyde, 2-Thiocarboxyaldehyde, Trans-2-pentenal, and Glutaraldehyde are treated with MTX to obtain MTX derivatives. The prediction of survival fraction of malignant glioma cells is carried out by Lasso, Elastic net and Soft PLS at different concentration levels of synthesized derivatives, including 400 μM, 200 μM, 100 μM, 50 μM, 25 μM and 12.5 μM. The cross-validated prediction error is minimised to optimise spectral wavelength selection and model parameters. It appears that the RMSE computed from test data is significantly varying with the change of models (p = 0.012), with the change of concentrations levels (p $$\le 0.001$$ ≤ 0.001 ) and with the change of combination of models and concentration level (p $$\le 0.001$$ ≤ 0.001 ). StPLS outperforms in predicting survival fraction of glioma cells at the concentration level 50 μM, 100 μM and 400 μM respectively with relative RMSE = 0.1,0.14 and 0.55. Lasso outperforms at the concentration level 12.5 μM, and 200 μM respectively with relative RMSE = 0.4 and 0.14. Elastic net outperforms at the concentration level 25 μM with relative RMSE = 0.8. Consistently appeared influential wavelength identifies the influential functional compounds which best predicts the survival fraction. Hence FTIR appears potential candidate for estimating survival fraction of MTX derivatives. |
| ArticleNumber | 18741 |
| Author | Iqbal, Mudassir Mehmood, Tahir |
| Author_xml | – sequence: 1 givenname: Tahir surname: Mehmood fullname: Mehmood, Tahir email: tahime@gmail.com organization: School of Natural Sciences (SNS), National University of Sciences and Technology (NUST) – sequence: 2 givenname: Mudassir surname: Iqbal fullname: Iqbal, Mudassir organization: School of Natural Sciences (SNS), National University of Sciences and Technology (NUST) |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34548518$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kstu1TAQhiNUREvpC7BAltiwCfia2BskVHGpVIkFsLYce5LjKic-tZ0j2PEabHg4ngTnpJSWBV7Yluefbzyj_3F1NIUJquopwS8JZvJV4kQoWWNKatVKRWr2oDqhmIuaMkqP7tyPq7OUrnBZgipO1KPqmHHBpSDypPr5KfQZ5U2EtAmjQzsTszcjGsGkjNL1bEoE7SI4b3MqQkBpjnu_L5o-Gpt9mFDo0daMfpjMlNEw-rA1yMI4JmQG46cCcr7vIUIJ2zDZckazZKZDKuRNyBG-mgy_vv9IyEEs_Oz3kJ5UD3szJji7OU-rL-_efj7_UF9-fH9x_uaytlyRXIuWcFz6sbjruMFt10BrhehJh2nTub4jvaWsaY0z1pSNdo4wLFopHKVOcXZaXaxcF8yV3kW_NfGbDsbrw0OIg14GY0fQRBDWiQJVttRyrWyg560pH6AKKJWF9Xpl7eZuC27tdrwHvR-Z_EYPYa8lF0IwXAAvbgAxXM-Qst76tMzTTBDmpKloBWsaSVSRPv9HehXmOJVRLSquGJV86Y6uKhtDShH6288QrBc36dVNurhJH9ykWUl6dreN25Q_3ikCtgpSCU0DxL-1_4P9DVs_3Wk |
| Cites_doi | 10.1016/j.bbamem.2009.02.016 10.1039/c0an00872a 10.1016/S0169-7439(00)00113-1 10.1039/C9AN00801B 10.1016/j.chemolab.2013.01.008 10.1016/j.ejmech.2018.09.027 10.1366/000370210792434350 10.1016/j.yexcr.2004.03.031 10.18637/jss.v033.i01 10.1093/rheumatology/keh512 10.1038/bjc.1997.164 10.1007/s00216-009-3140-y 10.4322/rbeb.2014.004 10.1007/s11749-008-0104-z 10.1002/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3 10.1016/S0378-4347(01)00402-9 10.1080/03602559.2018.1447126 10.1039/B307294K 10.1158/1078-0432.CCR-19-3717 10.1093/bioinformatics/bty199 10.1039/C4AN01831A 10.1097/00000441-195102000-00009 10.1016/j.microc.2012.06.016 10.1155/2010/910694 10.1111/j.1467-9868.2005.00503.x 10.1016/j.chemolab.2020.104124 10.32614/CRAN.package.plsVarSel 10.1007/BFb0062108 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2021 2021. The Author(s). The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2021 – notice: 2021. The Author(s). – notice: The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PIMPY PQEST PQQKQ PQUKI Q9U 7X8 5PM DOA |
| DOI | 10.1038/s41598-021-97891-3 |
| DatabaseName | SpringerOpen Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) ProQuest - Health & Medical Complete保健、医学与药学数据库 ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection (Proquest) (PQ_SDU_P3) ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) ProQuest Science Journals Biological Science Database Publicly Available Content Database (Proquest) (PQ_SDU_P3) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Student ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Biology Journals (Alumni Edition) ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Publicly Available Content Database CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: http://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2045-2322 |
| EndPage | 18741 |
| ExternalDocumentID | oai_doaj_org_article_1513b5bdf9cb4ad786ef47a14029e228 10_1038_s41598_021_97891_3 34548518 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | 0R~ 3V. 4.4 53G 5VS 7X7 88A 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD ABDBF ABUWG ACGFS ACSMW ADBBV ADRAZ AENEX AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE KQ8 LK8 M0L M1P M2P M48 M7P M~E NAO OK1 PIMPY PQQKQ PROAC PSQYO RIG RNT RNTTT RPM SNYQT UKHRP CGR CUY CVF ECM EIF NPM AAYXX CITATION 7XB 8FK K9. PQEST PQUKI Q9U 7X8 5PM AFPKN |
| ID | FETCH-LOGICAL-c491t-57140518c0bb4a07b6e7c55f1b026bdfb1fc2367adacaada2bd1305785d22d943 |
| IEDL.DBID | RPM |
| ISSN | 2045-2322 |
| IngestDate | Tue Oct 22 15:16:08 EDT 2024 Tue Sep 17 21:19:39 EDT 2024 Fri Oct 25 10:32:35 EDT 2024 Thu Oct 31 21:36:34 EDT 2024 Fri Nov 22 02:19:10 EST 2024 Wed Oct 16 00:44:05 EDT 2024 Fri Oct 11 20:36:29 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | 2021. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c491t-57140518c0bb4a07b6e7c55f1b026bdfb1fc2367adacaada2bd1305785d22d943 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455530/ |
| PMID | 34548518 |
| PQID | 2574932844 |
| PQPubID | 2041939 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_1513b5bdf9cb4ad786ef47a14029e228 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8455530 proquest_miscellaneous_2575366819 proquest_journals_2574932844 crossref_primary_10_1038_s41598_021_97891_3 pubmed_primary_34548518 springer_journals_10_1038_s41598_021_97891_3 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-09-21 |
| PublicationDateYYYYMMDD | 2021-09-21 |
| PublicationDate_xml | – month: 09 year: 2021 text: 2021-09-21 day: 21 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Scientific reports |
| PublicationTitleAbbrev | Sci Rep |
| PublicationTitleAlternate | Sci Rep |
| PublicationYear | 2021 |
| Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
| References | Liland, Almøy, Mevik (CR24) 2010; 64 Draux (CR12) 2009; 395 Kinder (CR4) 2005; 44 Liland, Høy, Martens, Sæbø (CR33) 2013; 122 Mehmood, Iqbal, Hassan (CR7) 2020; 206 CR37 CR36 CR35 CR34 Abdel Bary, Harmal, Saeed, Gouda (CR3) 2018; 57 Basu, Mitra, Liu, Schreiber, Clemons (CR21) 2018; 34 Zou, Hastie (CR32) 2005; 67 Gubner, August, Ginsberg (CR1) 1951; 221 Wald, Goormaghtigh (CR16) 2015; 140 Parachalil (CR18) 2019; 144 Hall, Giaccia (CR9) 2006 Batchelor, Kolak, Ciordia, Foster, Henson (CR5) 2003; 9 Martens, Næs (CR27) 1989 Derenne, Gasper, Goormaghtigh (CR19) 2010; 24 Gasper, Dewelle, Kiss, Mijatovic, Goormaghtigh (CR11) 2009; 1788 Lu (CR22) 2020; 26 Carvalho (CR15) 2014; 30 Derenne, Gasper, Goormaghtigh (CR17) 2011; 136 CR26 CR25 Gaigneaux (CR10) 2004; 297 Keleş, Chun (CR29) 2008; 17 Rubino (CR8) 2001; 764 CR23 Perez-Guaita (CR14) 2013; 106 Friedman, Hastie, Tibshirani (CR28) 2010; 33 Wang, Zhou, Liu (CR6) 2018; 158 Sæbø, Almøy, Aarøe, Aastveit (CR20) 2007; 20 Kasemsumran, Du, Murayama, Huehne, Ozaki (CR13) 2003; 128 Höskuldsson (CR30) 2001; 55 Kinsella, Smith, Pickard (CR2) 1997; 75 Tibshirani (CR31) 1997; 16 A Höskuldsson (97891_CR30) 2001; 55 CDS Carvalho (97891_CR15) 2014; 30 KH Liland (97891_CR33) 2013; 122 F Draux (97891_CR12) 2009; 395 J Friedman (97891_CR28) 2010; 33 H Martens (97891_CR27) 1989 97891_CR37 R Gubner (97891_CR1) 1951; 221 T Mehmood (97891_CR7) 2020; 206 G Lu (97891_CR22) 2020; 26 E Abdel Bary (97891_CR3) 2018; 57 97891_CR25 A Gaigneaux (97891_CR10) 2004; 297 97891_CR23 A Kinsella (97891_CR2) 1997; 75 EJ Hall (97891_CR9) 2006 H Zou (97891_CR32) 2005; 67 S Sæbø (97891_CR20) 2007; 20 R Tibshirani (97891_CR31) 1997; 16 K Liland (97891_CR24) 2010; 64 A Derenne (97891_CR17) 2011; 136 97891_CR26 S Kasemsumran (97891_CR13) 2003; 128 R Gasper (97891_CR11) 2009; 1788 D Perez-Guaita (97891_CR14) 2013; 106 DR Parachalil (97891_CR18) 2019; 144 97891_CR35 97891_CR36 A Derenne (97891_CR19) 2010; 24 TT Batchelor (97891_CR5) 2003; 9 W Wang (97891_CR6) 2018; 158 N Wald (97891_CR16) 2015; 140 97891_CR34 FM Rubino (97891_CR8) 2001; 764 S Keleş (97891_CR29) 2008; 17 A Basu (97891_CR21) 2018; 34 A Kinder (97891_CR4) 2005; 44 |
| References_xml | – volume: 1788 start-page: 1263 year: 2009 end-page: 1270 ident: CR11 article-title: Ir spectroscopy as a new tool for evidencing antitumor drug signatures publication-title: Biochim. Biophys. Acta (BBA) Biomemb. doi: 10.1016/j.bbamem.2009.02.016 contributor: fullname: Goormaghtigh – volume: 136 start-page: 1134 year: 2011 end-page: 1141 ident: CR17 article-title: The FTIR spectrum of prostate cancer cells allows the classification of anticancer drugs according to their mode of action publication-title: Analyst doi: 10.1039/c0an00872a contributor: fullname: Goormaghtigh – volume: 55 start-page: 23 year: 2001 end-page: 38 ident: CR30 article-title: Variable and subset selection in PLS regression publication-title: Chemom. Intell. Lab. Syst. doi: 10.1016/S0169-7439(00)00113-1 contributor: fullname: Höskuldsson – volume: 144 start-page: 5207 year: 2019 end-page: 5214 ident: CR18 article-title: Raman spectroscopy as a potential tool for label free therapeutic drug monitoring in human serum: The case of busulfan and methotrexate publication-title: Analyst doi: 10.1039/C9AN00801B contributor: fullname: Parachalil – volume: 122 start-page: 103 year: 2013 end-page: 111 ident: CR33 article-title: Distribution based truncation for variable selection in subspace methods for multivariate regression publication-title: Chemom. Intell. Lab. Syst. doi: 10.1016/j.chemolab.2013.01.008 contributor: fullname: Sæbø – volume: 158 start-page: 502 year: 2018 end-page: 516 ident: CR6 article-title: Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review publication-title: Eur. J. Med. Chem. doi: 10.1016/j.ejmech.2018.09.027 contributor: fullname: Liu – ident: CR37 – volume: 64 start-page: 1007 year: 2010 end-page: 10016 ident: CR24 article-title: Optimal choice of baseline correction for multivariate calibration of spectra publication-title: Appl. Spectrosc. doi: 10.1366/000370210792434350 contributor: fullname: Mevik – volume: 297 start-page: 294 year: 2004 end-page: 301 ident: CR10 article-title: The infrared spectrum of human glioma cells is related to their in vitro and in vivo behavior publication-title: Exp. Cell Res. doi: 10.1016/j.yexcr.2004.03.031 contributor: fullname: Gaigneaux – volume: 33 start-page: 1 year: 2010 ident: CR28 article-title: Regularization paths for generalized linear models via coordinate descent publication-title: J. Stat. Softw. doi: 10.18637/jss.v033.i01 contributor: fullname: Tibshirani – ident: CR35 – volume: 44 start-page: 61 year: 2005 end-page: 66 ident: CR4 article-title: The treatment of inflammatory arthritis with methotrexate in clinical practice: Treatment duration and incidence of adverse drug reactions publication-title: Rheumatology doi: 10.1093/rheumatology/keh512 contributor: fullname: Kinder – volume: 75 start-page: 935 year: 1997 end-page: 945 ident: CR2 article-title: Resistance to chemotherapeutic antimetabolites: A function of salvage pathway involvement and cellular response to DNA damage publication-title: Br. J. Cancer doi: 10.1038/bjc.1997.164 contributor: fullname: Pickard – volume: 395 start-page: 2293 year: 2009 end-page: 2301 ident: CR12 article-title: Ir spectroscopy reveals effect of non-cytotoxic doses of anti-tumour drug on cancer cells publication-title: Anal. Bioanal. Chem. doi: 10.1007/s00216-009-3140-y contributor: fullname: Draux – volume: 30 start-page: 54 year: 2014 end-page: 63 ident: CR15 article-title: Study of advanced rheumatoid arthritis publication-title: Revista Brasileira de Engenharia Biomédica doi: 10.4322/rbeb.2014.004 contributor: fullname: Carvalho – ident: CR25 – year: 1989 ident: CR27 publication-title: Multivariate Calibration contributor: fullname: Næs – volume: 20 start-page: 54 year: 2007 end-page: 62 ident: CR20 article-title: ST-PLS: A multi-dimensional nearest shrunken centroid type classifier via PLS publication-title: J. Chemom. contributor: fullname: Aastveit – volume: 17 start-page: 36 year: 2008 end-page: 39 ident: CR29 article-title: Comments on: Augmenting the bootstrap to analyze high dimensional genomic data publication-title: TEST doi: 10.1007/s11749-008-0104-z contributor: fullname: Chun – ident: CR23 – volume: 16 start-page: 385 year: 1997 end-page: 395 ident: CR31 article-title: The Lasso method for variable selection in the Cox model publication-title: Stat. Med. doi: 10.1002/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3 contributor: fullname: Tibshirani – volume: 764 start-page: 217 year: 2001 end-page: 254 ident: CR8 article-title: Separation methods for methotrexate, its structural analogues and metabolites publication-title: J. Chromatogr. B Biomed. Sci. Appl. doi: 10.1016/S0378-4347(01)00402-9 contributor: fullname: Rubino – volume: 57 start-page: 1906 year: 2018 end-page: 1914 ident: CR3 article-title: Design, synthesis, characterization, swelling and in vitro drug release behavior of composite hydrogel beads based on methotrexate and chitosan incorporating antipyrine moiety publication-title: Polym. Plast. Technol. Eng. doi: 10.1080/03602559.2018.1447126 contributor: fullname: Gouda – volume: 128 start-page: 1471 year: 2003 end-page: 1477 ident: CR13 article-title: Simultaneous determination of human serum albumin, -globulin, and glucose in a phosphate buffer solution by near-infrared spectroscopy with moving window partial least-squares regression publication-title: Analyst doi: 10.1039/B307294K contributor: fullname: Ozaki – volume: 26 start-page: 2582 year: 2020 end-page: 2594 ident: CR22 article-title: Predicting therapeutic antibody delivery into human head and neck cancers publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-19-3717 contributor: fullname: Lu – volume: 34 start-page: 3332 year: 2018 end-page: 3339 ident: CR21 article-title: RWEN: Response-weighted elastic net for prediction of chemosensitivity of cancer cell lines publication-title: Bioinformatics doi: 10.1093/bioinformatics/bty199 contributor: fullname: Clemons – volume: 9 start-page: 711 year: 2003 end-page: 715 ident: CR5 article-title: High-dose methotrexate for intraocular lymphoma publication-title: Clin. Cancer Res. contributor: fullname: Henson – volume: 140 start-page: 2144 year: 2015 end-page: 2155 ident: CR16 article-title: Infrared imaging of primary melanomas reveals hints of regional and distant metastases publication-title: Analyst doi: 10.1039/C4AN01831A contributor: fullname: Goormaghtigh – volume: 221 start-page: 176 year: 1951 end-page: 182 ident: CR1 article-title: Therapeutic suppression of tissue reactivity. 2. Effect of aminopterin in rheumatoid arthritis and psoriasis publication-title: Am. J. Med. Sci. doi: 10.1097/00000441-195102000-00009 contributor: fullname: Ginsberg – volume: 106 start-page: 202 year: 2013 end-page: 211 ident: CR14 article-title: Evaluation of infrared spectroscopy as a screening tool for serum analysis: Impact of the nature of samples included in the calibration set publication-title: Microchem. J. doi: 10.1016/j.microc.2012.06.016 contributor: fullname: Perez-Guaita – volume: 24 start-page: 55 year: 2010 end-page: 60 ident: CR19 article-title: Monitoring of metabolism perturbation in prostate pc-3 cancer cells by sub-lethal concentrations of methotrexate publication-title: Spectroscopy doi: 10.1155/2010/910694 contributor: fullname: Goormaghtigh – ident: CR34 – ident: CR36 – volume: 67 start-page: 301 issue: 2 year: 2005 end-page: 320 ident: CR32 article-title: Regularization and variable selection via the elastic-net publication-title: J. R. Stat. Soc. B doi: 10.1111/j.1467-9868.2005.00503.x contributor: fullname: Hastie – ident: CR26 – year: 2006 ident: CR9 publication-title: Radiobiology for the Radiologist contributor: fullname: Giaccia – volume: 206 start-page: 104124 year: 2020 ident: CR7 article-title: Prediction of antibacterial activity in ionic liquids through FTIR spectroscopy with selection of wavenumber by pls publication-title: Chemom. Intell. Lab. Syst. doi: 10.1016/j.chemolab.2020.104124 contributor: fullname: Hassan – volume: 26 start-page: 2582 year: 2020 ident: 97891_CR22 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-19-3717 contributor: fullname: G Lu – ident: 97891_CR37 doi: 10.32614/CRAN.package.plsVarSel – ident: 97891_CR34 – volume: 34 start-page: 3332 year: 2018 ident: 97891_CR21 publication-title: Bioinformatics doi: 10.1093/bioinformatics/bty199 contributor: fullname: A Basu – volume: 297 start-page: 294 year: 2004 ident: 97891_CR10 publication-title: Exp. Cell Res. doi: 10.1016/j.yexcr.2004.03.031 contributor: fullname: A Gaigneaux – volume: 764 start-page: 217 year: 2001 ident: 97891_CR8 publication-title: J. Chromatogr. B Biomed. Sci. Appl. doi: 10.1016/S0378-4347(01)00402-9 contributor: fullname: FM Rubino – volume: 106 start-page: 202 year: 2013 ident: 97891_CR14 publication-title: Microchem. J. doi: 10.1016/j.microc.2012.06.016 contributor: fullname: D Perez-Guaita – volume: 144 start-page: 5207 year: 2019 ident: 97891_CR18 publication-title: Analyst doi: 10.1039/C9AN00801B contributor: fullname: DR Parachalil – volume: 16 start-page: 385 year: 1997 ident: 97891_CR31 publication-title: Stat. Med. doi: 10.1002/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3 contributor: fullname: R Tibshirani – volume: 44 start-page: 61 year: 2005 ident: 97891_CR4 publication-title: Rheumatology doi: 10.1093/rheumatology/keh512 contributor: fullname: A Kinder – volume: 33 start-page: 1 year: 2010 ident: 97891_CR28 publication-title: J. Stat. Softw. doi: 10.18637/jss.v033.i01 contributor: fullname: J Friedman – volume: 75 start-page: 935 year: 1997 ident: 97891_CR2 publication-title: Br. J. Cancer doi: 10.1038/bjc.1997.164 contributor: fullname: A Kinsella – volume: 17 start-page: 36 year: 2008 ident: 97891_CR29 publication-title: TEST doi: 10.1007/s11749-008-0104-z contributor: fullname: S Keleş – volume: 55 start-page: 23 year: 2001 ident: 97891_CR30 publication-title: Chemom. Intell. Lab. Syst. doi: 10.1016/S0169-7439(00)00113-1 contributor: fullname: A Höskuldsson – volume: 136 start-page: 1134 year: 2011 ident: 97891_CR17 publication-title: Analyst doi: 10.1039/c0an00872a contributor: fullname: A Derenne – ident: 97891_CR36 – volume: 1788 start-page: 1263 year: 2009 ident: 97891_CR11 publication-title: Biochim. Biophys. Acta (BBA) Biomemb. doi: 10.1016/j.bbamem.2009.02.016 contributor: fullname: R Gasper – volume: 140 start-page: 2144 year: 2015 ident: 97891_CR16 publication-title: Analyst doi: 10.1039/C4AN01831A contributor: fullname: N Wald – volume-title: Multivariate Calibration year: 1989 ident: 97891_CR27 contributor: fullname: H Martens – volume: 67 start-page: 301 issue: 2 year: 2005 ident: 97891_CR32 publication-title: J. R. Stat. Soc. B doi: 10.1111/j.1467-9868.2005.00503.x contributor: fullname: H Zou – volume-title: Radiobiology for the Radiologist year: 2006 ident: 97891_CR9 contributor: fullname: EJ Hall – volume: 24 start-page: 55 year: 2010 ident: 97891_CR19 publication-title: Spectroscopy doi: 10.1155/2010/910694 contributor: fullname: A Derenne – volume: 64 start-page: 1007 year: 2010 ident: 97891_CR24 publication-title: Appl. Spectrosc. doi: 10.1366/000370210792434350 contributor: fullname: K Liland – ident: 97891_CR25 – ident: 97891_CR26 doi: 10.1007/BFb0062108 – volume: 221 start-page: 176 year: 1951 ident: 97891_CR1 publication-title: Am. J. Med. Sci. doi: 10.1097/00000441-195102000-00009 contributor: fullname: R Gubner – volume: 395 start-page: 2293 year: 2009 ident: 97891_CR12 publication-title: Anal. Bioanal. Chem. doi: 10.1007/s00216-009-3140-y contributor: fullname: F Draux – volume: 122 start-page: 103 year: 2013 ident: 97891_CR33 publication-title: Chemom. Intell. Lab. Syst. doi: 10.1016/j.chemolab.2013.01.008 contributor: fullname: KH Liland – volume: 158 start-page: 502 year: 2018 ident: 97891_CR6 publication-title: Eur. J. Med. Chem. doi: 10.1016/j.ejmech.2018.09.027 contributor: fullname: W Wang – volume: 9 start-page: 711 year: 2003 ident: 97891_CR5 publication-title: Clin. Cancer Res. contributor: fullname: TT Batchelor – volume: 206 start-page: 104124 year: 2020 ident: 97891_CR7 publication-title: Chemom. Intell. Lab. Syst. doi: 10.1016/j.chemolab.2020.104124 contributor: fullname: T Mehmood – ident: 97891_CR23 – volume: 30 start-page: 54 year: 2014 ident: 97891_CR15 publication-title: Revista Brasileira de Engenharia Biomédica doi: 10.4322/rbeb.2014.004 contributor: fullname: CDS Carvalho – volume: 57 start-page: 1906 year: 2018 ident: 97891_CR3 publication-title: Polym. Plast. Technol. Eng. doi: 10.1080/03602559.2018.1447126 contributor: fullname: E Abdel Bary – volume: 20 start-page: 54 year: 2007 ident: 97891_CR20 publication-title: J. Chemom. contributor: fullname: S Sæbø – ident: 97891_CR35 – volume: 128 start-page: 1471 year: 2003 ident: 97891_CR13 publication-title: Analyst doi: 10.1039/B307294K contributor: fullname: S Kasemsumran |
| SSID | ssj0000529419 |
| Score | 2.38432 |
| Snippet | Chemotherapy appeared to be a significant advancement in cancer research, with fewer side effects. Methotrexate (MTX) is a widely used anticancer drug with... Abstract Chemotherapy appeared to be a significant advancement in cancer research, with fewer side effects. Methotrexate (MTX) is a widely used anticancer drug... |
| SourceID | doaj pubmedcentral proquest crossref pubmed springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 18741 |
| SubjectTerms | 631/45 639/705/531 692/308 Aldehydes Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Antitumor agents Arthritis Benzaldehyde Brain Neoplasms - drug therapy Brain Neoplasms - pathology Cancer Cancer research Cell Survival - drug effects Chemotherapy Drug dosages Glioma Glioma - drug therapy Glioma - pathology Glioma cells Humanities and Social Sciences Humans Least-Squares Analysis Metabolism Methotrexate Methotrexate - pharmacology Methotrexate - therapeutic use multidisciplinary Science Science (multidisciplinary) Side effects Solvents Spectrum analysis Survival Wavelength |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagEhIXxJtAQUbiBlHXjyT2kUernrgUJG6WYzvLSm12u04QvfVvcOHH8UuYsbMLy0NcuOSQONJkZjyPjOcbQp7ZDsyiqnVpnQilrIQrtRWs5DbBoQgwh9iNfHzSvP2g3hwiTM521BeeCcvwwJlxB-CRRFu1vtOuldY3qg6dbCzkBVwHznOb76z-KZnKqN5cS6anLpmZUAcRPBV2k-GJhEZpVoodT5QA-_8UZf5-WPKXimlyREc3yY0pgqQvM-W3yJXQ3ybX8kzJizvk6wkYVjqAiCJWlugKPxHWn-KQHhrPR2w4oqs1FmiGCAsDjSPYC9A42q1zmwNddvQMAvQ5npKh89PF8sxS_MUfqZ3bBUSUdDNYZaAOGx_7CX03pldxKvWwDp8hjv12-SVSD2r-KSGMx7vk_dHhu9fH5TSEoXRSs6GsENGvYsrNWuD_rGnr0Liq6lgL2RuIpWWdQxQ4662zcOGtB7eIEDqec6-luEf2-mUfHhCqdNdaK6QLTMiulpb7jvmZ9aqWkGjKgjzfCMSsMtaGSTVyoUwWnwHxmSQ-IwryCmW2XYk42ekGaI-ZtMf8S3sKsr-RuJk2bzRgxSSEtYmip9vHsO2Q0bYPyzGtqURdQzxVkPtZQbaUCAlpILCsIM2O6uyQuvukX3xM0N5KVjjHqSAvNkr2g6y_s-Lh_2DFI3Kd4-7AihvbJ3vDegyPydXoxydpb30HekMsfA priority: 102 providerName: Directory of Open Access Journals |
| Title | Soft threshold partial least squares predicts the survival fraction of malignant glioma cells against different concentrations of methotrexate’s derivatives |
| URI | https://link.springer.com/article/10.1038/s41598-021-97891-3 https://www.ncbi.nlm.nih.gov/pubmed/34548518 https://www.proquest.com/docview/2574932844 https://search.proquest.com/docview/2575366819 https://pubmed.ncbi.nlm.nih.gov/PMC8455530 https://doaj.org/article/1513b5bdf9cb4ad786ef47a14029e228 |
| Volume | 11 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELboSkhcEG8Cy8pI3CDbJnYePsKyq72AkBYkbpbjR6nUJiVOENz4G1z4cfwSZpykbHlcuOTQuMrEMx5_zsx8Q8gT5cAtlrmIlWY25hnTsVAsiVMV6FAYuEOsRj6_KF6_L1-eIk1ONtXChKR9Xa2O6_XmuF59CLmV242eT3li8zevTkqeYbeb-YzMABteOqIPhN6p4IkYC2QWrJx72KSwkAyTEYpSJDE2z2EcsHqGvT4u7UeBtv9vWPPPlMnf4qZhOzq7Qa6POJI-H-S9Sa7Y-ha5OnSW_HKbfL8A90o7UJTH-BLd4ovB-DW26qH-Y49lR3TbYpim8zDQUt-D1wC7o64dih1o4-gGYPoSc2Xocr1qNorih35P1VKtAFfSqb1KRzWWP9YjB68Pf8Xe1F1rPwOa_fH1m6cGjP1T4Bn3d8i7s9O3J-fx2Ioh1lwkXZwhrx_Mll5UFVeLosptobPMJRWc4SrjqsRp5IJTRmkFl7QysDkikY5JUyM4u0sO6qa29wkthauUYlzbhHGXc5Ual5iFMmXO4bjJI_J0UojcDowbMkTKWSkHTUrQpAyalCwiL1Bnu5HIlh1-aNqlHG1GAqphVQZiCg3Sm6LMreOFgldKhU3TMiKHk8bluIS9BF_GAdwGiR7vbsPiw4lWtW36MCZjeQ6oKiL3BgPZSTIZWESKPdPZE3X_Dth7IPge7TsizyYj-yXWv6fiwX8_6CG5luLqwGBbckgOura3j8jMm_4ofKM4CivsJ6EMLdk |
| link.rule.ids | 230,315,729,782,786,866,887,2106,27933,27934,53801,53803 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZoEYIL70KggJG4QbpJ7LyOUFotoq2QWiRulmM7y0q7yRInCG78DS78OH4JM06ydHlcetnD2tmd2N-Mx5qZbwh5Jkswi1mS-1Ix4_OYKT-XLPQj6ehQGJhDrEaenqYnH7LXB0iTE4-1MC5pXxXzvWqx3KvmH11u5WqpJmOe2OTd8X7GY-x2M9kil0Ffg_DcJb2n9I5yHuZDiUzAsomFYwpLyTAdIc3y0Mf2OYyDtx5jt49zJ5Ij7v-Xt_l30uQfkVN3IB3euOCr3CTXBw-UvuyHb5FLprpNrvQ9Kb_eIT9OwTDTFrbYYmSKrvB3YP4Cm_xQ-6nDgiW6ajDA01qYaKjtwN4AYmnZ9GUStC7pEhz8GWbZ0NliXi8lxRCBpXIm5-CR0rExS0sVFk5WA3uvdY9iV-u2MV_AD_757bulGtTks2Mot3fJ-8ODs_2pPzRx8BXPw9aPkREQVlkFRcFlkBaJSVUcl2EBt79Cl0VYKmSRk1oqCR9RoeFYRQoeHUU652yHbFd1Ze4TmuVlISXjyoSMlwmXkS5DHUidJRwuqtwjz8eNFKueq0O4GDvLRI8AAQgQDgGCeeQV7vV6JvJsuy_qZiaGLRLgD7EiBjFzBdLrNEtMyVMJrxTlJooyj-yOSBGD8lsBVpCDW-wkeroeBrXFhZaVqTs3J2ZJAv6YR-71wFpLMgLTI-kG5DZE3RwBeDlq8AFOHnkxgvO3WP9figcX_qMn5Or07PhIHL05efuQXItQwzBkF-6S7bbpzCOyZXX32OnnL_5XQms |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZoEYgLb2iggJG4Qbqb2Hkdoe2qCKgqFSRuluPHstJudhsnCG78DS78OH4JM06ydHlc4LKHZJKd2J_HY83MN4Q8kRbMYp4WoVTMhDxhKiwki8JYejoUBuYQq5GPTrPj9_nBIdLkrFt9-aR9Vc72qvlir5p98LmVq4UaDXlio5M3-zlPsNvNaKXtaItchDU7ZucO6h2td1zwqOjLZMYsHznYqrCcDFMSsryIQmyhwzh47Al2_Di3K3ny_j95nL8nTv4SPfWb0uTaf3zOdXK190Tp807kBrlgqpvkUteb8vMt8u0UDDRtYKodRqjoCt8F8nNs9kPdWYuFS3RVY6CncSBoqGvB7gByqa27cgm6tHQBjv4Us23odD5bLiTFUIGjcipn4JnSoUFLQxUWUFY9i6_zj2J366Y2n8Af_v7lq6MalstHz1TubpN3k8O3-0dh38whVLyImjBBZkAYaTUuSy7HWZmaTCWJjUo4BZbalpFVyCYntVQSfuJSw_aKVDw6jnXB2R2yXS0rs0NoXthSSsaViRi3KZextpEeS52nHA6sPCBPh8kUq46zQ_hYO8tFhwIBKBAeBYIF5AXO91oS-bb9hWU9Ff00CfCLWJmAmoUC7XWWp8byTMInxYWJ4zwguwNaRG8EnABryME99ho9Xt-G5YsDLSuzbL1MwtIU_LKA3O3AtdZkAGdAsg3Ybai6eQcg5inCe0gF5NkA0J9q_X0o7v3zHz0il08OJuL1y-NX98mVGBcZRu6iXbLd1K15QLacbh_6JfoD5qBE6w |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Soft+threshold+partial+least+squares+predicts+the+survival+fraction+of+malignant+glioma+cells+against+different+concentrations+of+methotrexate%E2%80%99s+derivatives&rft.jtitle=Scientific+reports&rft.au=Mehmood%2C+Tahir&rft.au=Iqbal%2C+Mudassir&rft.date=2021-09-21&rft.pub=Nature+Publishing+Group+UK&rft.eissn=2045-2322&rft.volume=11&rft.issue=1&rft_id=info:doi/10.1038%2Fs41598-021-97891-3&rft.externalDocID=10_1038_s41598_021_97891_3 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon |